NIMBUS Biotechnology introduces a High-Throughput Rat Serum Albumin (RSA)TRANSIL® „ready-to-go” kit in a 96 or 384 well format

Leipzig (Germany) February 28, 2006. – NIMBUS Biotechnology, known for its innovative high-throughput early ADME TRANSIL® assay platform and its fast and reliable NIMBUS screening service is now offering a Rat Serum Albumin TRANSIL® assay. This is in addition to the already well established and extensively used TRANSIL® Human Serum Albumin platform for protein binding studies in the drug discovery area. The ability of drug candidates to bind to plasma proteins or tissue is an important variable which influences the availability and efficacy of a compound in-vivo. Generally, only the unbound fraction of the drug is able to permeate membranes, exert pharmacological activity, be filtered in the renal tubuli, or be cleared by drug-metabolizing enzymes, therefore the serum bound to the proteins is mainly responsible for the distribution of a compound in the human body.

The proprietary TRANSIL® technology, developed to overcome the restrictions of traditional methods like time-consuming dialysis or ultrafiltration, runs fully automated in SBS standardized microtiter plates (“ready to go” plates) on state of the art automated platforms permitting to screen even complete compound libraries. This bead based technology opens an early, fast and precise access to two significant ADME related parameters, namely the partitioning of a compound between a lipid membrane and an aqueous phase as well as the binding of drugs to serum albumins. Two assay formats are available, which are configured for the different purposes of measurements and phases of the screening process, in both the 96 and 384 well plate format.

Wolfgang Lerch, CEO of NIMBUS Biotechnology, stated today, “NIMBUS Biotechnology has taken a further step in adding another modern tool to the drug discovery process. To test drug candidates at an early stage for cost reduction and increased throughput is becoming more important by the day. Today rat is a frequently used animal model in drug development leading to a growing demand of in-vitro rat data already at early stages. The TRANSIL® technology of NIMBUS offers such a solution by making it possible to test thousands of compounds for protein binding using rat serum albumin every day.

NIMBUS Biotechnologie GmbH
Eilenburger Strasse 4
D-04317 Leipzig
Germany

Contact Information

Wolfgang Lerch

CEO

NIMBUS Biotechnologie GmbH

Contact via E-mail